天眼查App显示，近日，上海鑫顺悦医疗器械有限公司成立，法定代表人为李琼，注册资本50万人民 币，经营范围为一般项目：第一类医疗器械销售；第二类医疗器械销售；消毒剂销售（不含危险化学 品）；办公用品销售；五金产品批发；日用百货销售；电子产品销售；仪器仪表销售；建筑材料销售； 计算机软硬件及辅助设备批发；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；商 务代理代办服务；信息咨询服务（不含许可类信息咨询服务）；会议及展览服务；专用设备修理。（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目：第三类医疗器械经营。（依法 须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件 为准）。 ...

天眼查App显示，近日，上海康思美医疗器械有限公司成立，法定代表人为王桂琴，注册资本50万人民 币，经营范围为一般项目：第一类医疗器械销售；第二类医疗器械销售；企业管理咨询；信息咨询服务 （不含许可类信息咨询服务）；仪器仪表销售；电子元器件与机电组件设备销售；生物基材料技术研 发；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；建筑陶瓷制品销售；电子产品 销售；会议及展览服务。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目： 第三类医疗器械经营。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以 相关部门批准文件或许可证件为准）。 ...

Core Insights - Shanghai Kangruixingdi Medical Equipment Co., Ltd. has been established with a registered capital of 1 million RMB and is represented by Sun Shujuan [1] Company Overview - The company is engaged in the operation of Class III medical devices, which require approval from relevant authorities before business activities can commence [1] - The general business scope includes sales of Class I and Class II medical devices, information consulting services (excluding licensed consulting), technical services, and various retail and service activities [1] Business Activities - Specific activities include sales of disinfectants (excluding hazardous chemicals), sports equipment retail, computer hardware and software sales, marketing planning, and conference services [1] - The company also provides professional cleaning, disinfection services, rehabilitation aid adaptation services, and equipment repair services [1]

Core Insights - The "China Pharmaceutical Valley" in Daxing is actively promoting international expansion for pharmaceutical companies, with over 20 companies successfully entering overseas markets and hundreds of products launched internationally [2][3] - The Daxing Biopharmaceutical Industry Base has established a comprehensive "outbound service platform" to support companies in their international endeavors, integrating resources from government, industry organizations, and overseas institutions [3][4] - The government is focused on addressing challenges faced by companies in international markets, providing full-process guidance on overseas registration, data compliance, and intellectual property layout [4] Group 1: International Expansion - Daxing has hosted the "3rd China-Germany Cross-Border Pharmaceutical Health Industry Cooperation Exchange Conference," signaling a commitment to accelerate overseas market expansion for pharmaceutical enterprises [1] - Companies like Baiyao and Minhai Biotech have reported significant international sales, with Baiyao achieving nearly 70% of its sales from overseas markets [2] - Tongrentang, a traditional Chinese medicine leader, reported overseas revenue of 592 million yuan, a year-on-year increase of 21.52% [2] Group 2: Supportive Infrastructure - The upgraded "outbound service platform" has enabled companies like Amite Medical to secure larger overseas orders, moving beyond small transactions [3] - The platform fosters collaboration among companies with outbound experience, allowing for shared resources and channels to facilitate international market entry [3] - The Daxing Biopharmaceutical Base aims to enhance its vitality through increased openness and support for companies in developing global perspectives and capabilities [3]

证券之星消息，11月12日南向资金减持6100.0股高视医疗（02407.HK）。近5个交易日中，获南向资金 减持的有5天，累计净减持4.02万股。近20个交易日中，获南向资金减持的有20天，累计净减持33.25万 股。截至目前，南向资金持有高视医疗（02407.HK）605.28万股，占公司已发行普通股的4.08%。 高视医疗科技有限公司是一家主要从事眼科医疗业务的中国公司。该公司经营四个分部。自有产品分部 开发及生产手术设备及相关配套软件、内光透镜、眼科疾病诊断及治疗设备。经销分部销售品牌眼科医 疗器械及其耗材。技术服务分部提供保修服务、维护服务及售后服务相关的耗材。其他分部主要从事设 备租赁业务和知识产权代理服务。该公司的产品广泛应用于眼底病、白内障、青光眼、屈光、验光、眼 表、儿童眼科等眼科亚专科疾病的检查、治疗和矫正。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-12 | 605 ...

截至2025年11月12日收盘，伟思医疗(688580)报收于48.2元，上涨0.06%，换手率1.97%，成交量1.88万 手，成交额9160.83万元。 当日关注点 交易信息汇总资金流向 11月12日主力资金净流入1542.31万元，占总成交额16.84%；游资资金净流入398.88万元，占总成交额 4.35%；散户资金净流出1941.19万元，占总成交额21.19%。 股本股东变化股东增减持 11月12日伟思医疗发布公告，股东南京志达创业投资中心(有限合伙)于2025年11月5日至2025年11月11 日间合计减持44.86万股，占公司目前总股本的0.4684%，变动期间该股股价下跌7.58%，截至11月11日 收盘报48.17元。 公司公告汇总 南京伟思医疗科技股份有限公司关于股东减持股份计划时间届满暨减持结果公告 南京伟思医疗科技股份有限公司股东南京志达创业投资中心（有限合伙）在2025年8月14日至11月11日 期间，通过集中竞价和大宗交易方式合计减持公司股份1,176,782股，占公司总股本的1.2287%，减持价 格区间为45.00至57.50元/股，减持总金额为59,516,273.90元。 ...

Core Points - The company has decided to repurchase and cancel 1,715,024 shares from its 2024 employee stock ownership plan due to unmet performance targets [1][3][5] Group 1: Repurchase and Cancellation Details - The decision for the repurchase and cancellation was approved during the board meeting on August 19, 2025, and subsequently at the second extraordinary general meeting of shareholders on September 4, 2025 [2][4] - The repurchase is set to be completed by November 17, 2025, with the company applying for the transfer of shares to a dedicated repurchase account [4] Group 2: Financial Performance - For the fiscal year 2024, the company reported an audited revenue of 567 million and a net profit attributable to shareholders of 57 million, which was adjusted to 69 million after excluding non-recurring losses [3] Group 3: Impact on Shareholding Structure - Following the cancellation, the total share capital will decrease from 321,315,646 shares to 319,600,622 shares, resulting in a slight increase in the shareholding percentage of major shareholders from 8.97% to 9.01% [4][5] Group 4: Company Outlook - The repurchase and cancellation of shares are not expected to materially affect the company's financial status, operational results, or shareholder equity [5]

Group 1 - A-share companies are increasingly seeking listings on the Hong Kong Stock Exchange, with over 80 companies having submitted applications this year alone [1][3] - The number of A+H listed companies has reached 160, with 16 companies successfully listing in Hong Kong this year, surpassing the total from the previous five years [2][3] - Major A-share companies that have recently listed include Ningde Times, which raised nearly 40 billion HKD, and others like Sails and Sany Heavy Industry, each raising over 10 billion HKD [2] Group 2 - The sectors attracting A-share companies to Hong Kong include biomedicine, technology, and consumer goods, reflecting investor interest in these areas [3][4] - The Hong Kong Stock Exchange has optimized its listing mechanisms, making it easier for companies to access capital, which is crucial for their growth [4] - The trend of A+H listings is driven by the desire of mainland companies to enter international markets, leveraging Hong Kong's unique position and regulatory environment [5] Group 3 - The Hong Kong Stock Exchange has seen record revenue and net profit in the first three quarters of the year, driven by high trading activity and a surge in new listings [6] - There are currently around 300 listing applications being processed, with half from new economy sectors such as electric vehicles and biotechnology [6] - Despite the overall positive trend, some new listings have faced challenges, with instances of stocks dropping below their issue price on debut, leading to delays in some IPOs [6][7]

◎记者 朱妍 沪指4000点"争夺战"仍在上演。近期，科技赛道回调，消费、银行等板块接棒上行，市场风格与行业板 块轮动加快，公募也在调整布局。多位基金经理表示，当下更关注持仓结构的优化，着力挖掘并捕捉具 备阿尔法的优质标的。 上证指数围绕4000点反复震荡，主动权益类基金整体仓位维持在历史高位。据信达证券测算，截至11月 9日，普通股票型基金的平均仓位约为91.46%，较11月2日的91.34%提升0.12个百分点。同时，偏股混合 型基金同期平均仓位为89.92%，"固收+"基金的平均仓位环比提升0.03个百分点。 "市场波动加剧，我在投资上没有三季度那么激进，但也没降低仓位，而是进行了持仓结构的优化。一 边加入消费、红利等资产；一边寻找个股阿尔法，以提升产品的超额收益。"沪上某权益类基金经理透 露。 与此同时，11月以来公募基金的新发节奏还在提升。公募排排网数据显示，按认购起始日统计，11月10 日至16日这一周，全市场共有39只新基金启动募集，环比增长5.41%，且11月以来已连续两周增长。 从近期新基金的建仓节奏看，许多基金已在震荡中快速出手。Choice数据显示，近三个月（8月12日至 11月12日） ...

长沙晚报掌上长沙11月12日讯（全媒体记者 刘军）A股三大指数12日震荡整理，沪指险守4000点关口。 截至收盘，沪指跌0.07%，收报4000.14点；深证成指跌0.36%，收报13240.62点；创业板指跌0.39%，收 报3122.03点。沪深两市成交19450亿元，较11日缩量486亿元。 行业板块涨少跌多，保险、采掘行业、医药商业、医疗器械、美容护理板块涨幅居前，光伏设备、非金 属材料、风电设备、电源设备、电网设备、电子化学品板块跌幅居前。个股方面，上涨股票1758只，涨 停77只；下跌股票3563只，跌停10只。 在蓝筹股护盘的影响下，12日两市大盘探底回升，然后再次回踩，沪市最低回踩3980点附近。下午，大 盘逐步回升，最终以微跌报收。从消息面上来看，在12日启幕的上海证券交易所国际投资者大会上，中 国证监会相关负责人表示，要强化战略性力量储备和稳市机制建设，提升资本市场内在稳定性，坚决防 止市场大起大落、急涨急跌。该消息无疑给市场注入了一针强心剂，让投资者吃下定心丸。 惠博普的主营业务为油气工程及运营服务、环境工程及服务、油气资源开发及利用。2025年三季报，公 司每股收益0.01元，归母净利 ...